Evonik Oxeno GmbH & Co. KG
USPTO PatentsView assignee record - 21 granted patents across 15 technology areas, recorded in grant years 2024–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07C (Acyclic OR Carbocyclic Compounds).
The verdict
According to USPTO PatentsView, Evonik ranks #13,977 of 49,997 tracked US assignees by granted-patent volume, with 21 patents across 15 technology areas.
- #13,977
- of 49,997 US assignees by volume
- Top 8%
- by Innovation Score (54.1/100)
- 16.3
- avg claims per patent
USPTO PatentsView assignee plate
Corpus R13977 · Foreign Corporation #13,977 · 21 grants
GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH
- GRANTS-SMALL 21 grants
- MID-PACK #13,977/49,997
- PHOTO-FINISH Energy Full
- CPC-FOCUS C07C · 15 areas
- INNOV-PAR 54.1/100
- CLAIMS-RICH 16.3 claims/avg
- TYPE-FRNCORP Foreign Corp
- SPAN-YRS 2024–2025 · 2y
- BOOK-RICH 9/10 fields
Nearest grant-volume peer: Energy Full Electronics Co., Ltd (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Evonik’s 54.1 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Evonik
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Evonik Oxeno & KG · this assignee
Evonik Oxeno & KG · this assignee
54 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Evonik's Innovation Score is 54.1/100 (top 8% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Evonik?
Each dot is one of Evonik’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Evonik’s own 16.3 claims/patent is at or below the 18.9 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Evonik's grants concentrate
Evonik Oxeno GmbH & Co. KG is a focused PatentsView assignee: 15 CPC subclasses with 76.2% of grants classified under C07C (Acyclic OR Carbocyclic Compounds). By volume, Evonik sits between Energy Full Electronics Co., Ltd and EyePoint Pharmaceuticals, Inc..
Evonik's three-year grant acceleration
Evonik Oxeno GmbH & Co. KG shows 14 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Evonik's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Energy Full
Energy Full Electronics Co., Ltd
21 patents
- Epivax
EpiVax Inc.
21 patents
- Erber
Erber AG
21 patents
- Etagen
EtaGen, Inc.
21 patents
- Exabeam
Exabeam, Inc.
21 patents
- Excelitas Canada
Excelitas Canada, Inc.
21 patents
- Exegy Incorporated
Exegy Incorporated
21 patents
- Eyepoint Pharmace…
EyePoint Pharmaceuticals, Inc.
21 patents
- Evonik Oxeno & KG ◀
Evonik Oxeno GmbH & Co. KG
21 patents
What this shows Evonik holds 21 patents at rank #13,978, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Evonik
By rank, the assignees closest to #13,978 in granted patent volume.
- Energy Full Electronics Co., Ltd #13,974 · 21 patents
- EpiVax Inc. #13,975 · 21 patents
- Erber AG #13,976 · 21 patents
- EtaGen, Inc. #13,977 · 21 patents
- Exabeam, Inc. #13,979 · 21 patents
- Excelitas Canada, Inc. #13,980 · 21 patents
- Exegy Incorporated #13,981 · 21 patents
- EyePoint Pharmaceuticals, Inc. #13,982 · 21 patents
Leaders in C07C (Acyclic OR Carbocyclic Compounds)
Other assignees with the most granted patents in Evonik's primary technology class.
Evonik's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
54 Top 8% higher than 92% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2024–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2024 | 14 | 66.7% |
| 2025partial year | 7 | 33.3% |
Which technologies does Evonik Oxeno GmbH & Co. KG patent most?
Top 15 of 15 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Evonik Oxeno GmbH & Co. KG's patent record in context - here's where to go next.
- Evonik Oxeno GmbH & Co. KG's lead technology class is C07C (Acyclic OR Carbocyclic Compounds), 76.2% of its portfolio - see every assignee active in that class. Explore C07C
- Ranked #13,977 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Evonik Oxeno GmbH & Co. KG against Energy Full Electronics Co., Ltd, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 54.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.